Sareum (LON:SAR) Stock Price Down 13% – Should You Sell?

Sareum Holdings plc (LON:SAR) dropped 13% on Thursday . The company traded as low as GBX 13.88 ($0.19) and last traded at GBX 13.88 ($0.19). Approximately 468,628 shares changed hands during mid-day trading, an increase of 6% from the average daily volume of 440,717 shares. The stock had previously closed at GBX 15.95 ($0.21).

Sareum Stock Up 3.4%

The company has a market capitalization of £19.05 million, a PE ratio of -3.61 and a beta of -1.08. The firm’s 50-day moving average is GBX 15.96 and its 200-day moving average is GBX 18.69.

Sareum (LON:SAR) last released its quarterly earnings results on Tuesday, March 25th. The company reported GBX (0.90) (($0.01)) earnings per share (EPS) for the quarter. As a group, equities research analysts predict that Sareum Holdings plc will post -3.8 EPS for the current year.

Insider Buying and Selling

In other Sareum news, insider Stephen Parker bought 84,033 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average price of GBX 12 ($0.16) per share, with a total value of £10,083.96 ($13,561.00). 5.02% of the stock is currently owned by insiders.

Sareum Company Profile

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.